Business Context and Reporting Period
This Form 8-K filing by Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) reports a corporate governance event. The report date is November 18, 2025, with the document signed on November 21, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the departure of a senior executive:
- Keith Kucinski, Chief Financial Officer, notified the Company of his intention to resign.
- The resignation is effective January 17, 2026.
- The departure is to pursue other opportunities and was not the result of any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, outlook, or management commentary on business strategy. No new risks or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the timeline for the appointment of an interim or permanent replacement for the CFO role.
- Review the Company's most recent 10-K or 10-Q filings for current financial status, as this 8-K contains no financial data.
- Monitor future filings for any transition plans regarding financial reporting and investor relations.